Journal of Clinical Case Reports

Department of Molecular Oncology, Fujita Health University School of Medicine, Nagoya 470-1192, Japan

Publications

• Case Report   
  Enzalutamide for Primary Immune Prostate Cancer in Routine Clinical Practice: Results from a Rare Metastasis Study in Japan
  Author(s): Kento Tomohisa*, Toma Abe, Ken Sota, Akiho Kato, Shigeo Sakurako, Tokuda Kaoru and Taka Yoshizawa
  
  Introduction: The effectiveness and safety of romiplostim were evaluated by immune thrombocytopenia (ITP) phase (newly diagnosed/ persistent/chronic) at romiplostim initiation. Methods: This is a post hoc analysis of a prospective, Japanese, multicentre, observational study in adults with ITP who received ≥ 1 dose of romiplostim. Follow-up data were collected for ≤ 2 years. Outcomes included overall platelet response (≥ 1 platelet count ≥ 50 × 109/L at 2–24 weeks after romiplostim initiation) or durable platelet response (≥ 75% of measurements ≥ 50 × 109/L at 14–24 weeks) and adverse drug reactions (ADRs), evaluated by ITP phase. Results: Data from 96 patients were analysed (newly diagnosed, n =18; persistent, n=25; chronic, n=53). During the 2- to 24-week fol.. Read More»
  DOI: 10.37421/2165-7920.2022.12.1534

  Abstract HTML PDF